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Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is leading to a great 
number of mortalities throughout the world these days. To date, no specific drug or 
vaccine has been developed so the only available options are preventive strategies like 
quarantine. In summer, the transmission rate of this virus may reduce, however, it is 
possible that the disease prevails and becomes endemic.
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Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2), the cause of the new coronavirus disease, that was 
named to COVID-19 by World Health Organization (WHO) is 
currently a global health emergency. Although the most infect-
ed cases experience mild symptoms, but death due to subse-
quent complications is possible [1]. Over one and a half million 
people worldwide have been infected until now (April 11th) 
and more than 200 countries have had confirmed cases. Un-
fortunately, the pandemic has led to more than 100,000 deaths 
globally [2].
To date, no specific medication or vaccine has been developed 
and researchers are trying to find an effective option for reduc-
ing the morbidity and mortality [3]. Drug discovery demands 
great efforts and takes a great deal of time. A precise knowledge 
about the pathophysiology of disease is essential and then the 
process is followed by complex procedures of investigating the 
pharmacokinetics, safety,etc. of the drug [4]. This issue empha-
sizes the need for other strategies to control the pandemic and 
also gathers attention to other aspects of the disease. There are 
some articles indicating that SARS-CoV-2, like severe acute 
respiratory syndrome (SARS) and influenza, may be affected 
by meteorological parameters such as humidity and tempera-
ture. Low temperature is associated with highermortality rate 
due to respiratory infections. Therefore, with the beginning of 
summer lower rate of transmission is expected [5, 6]. 
A similar situation dates back to 2003 when an epidemic of 
SARS was reported by WHO, originating from China. Hotspot 
regions of infection were China, Singapore, Vietnam, and Can-
ada. In less than four months, about 8,000 people in more than 
25 countries had been infected with SARS and about 700 peo-
ple had died. The pandemic was declared as a global alert On 
March 12, 2003. Although many efforts were made to find an 
effective drug or vaccine, not much progress was made. WHO 
strategies to control the disease were limited to isolation of 
the infected patients, quarantine of suspected individuals, and 
screening the travelers from endemic areas. These strategies 
were efficient and SARS was eradicated finally [7, 8].
Another example of these virus genera epidemic is the Middle 
East Respiratory Syndrome-coronavirus (MERS-CoV) out-
break in 2015. Despite the lack of vaccines or medications, 
aggressive quarantine strategy was a helpful tool for prevent-
ing the spread of infection and controlling the epidemic. The 
epidemic lasted for 2 months and after several weeks of not re-
porting any new cases, WHO declared the end of the outbreak. 
However, the source of the virus, Saudi Arabia, confirmed 
some new cases for years afterwards. Transmission of MERS-
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CoV is defined as both sporadic zoonotic (camel-to-human) 
and intra-familial (human-to-human). Although human-to-hu-
man rate of transmission is low for this viruse in comparison 
with SARS-CoV-2, but it is the main route of transmission 
throughout the community. It can also be concluded that the 
camel-to-human transmission leads to new sporadic cases in 
Saudi Arabia and provides a permanent source of the virus [9, 
10]. 
Zika virus was first seen sporadically in Africa and Asia but 
in 2015 the virus spread from the Pacific to Brazil and in less 
than a year, quickly expanded throughout the America and then 
became pandemic. The patients were asymptomatic in 80% of 
cases, which made the disease highly contagious. No specific 
drug or vaccine was approved for Zika virus, and patients were 
treated symptomatically. Since the virus could be transmitted 
in a variety of routes, preventing the transmission was the main 
way to deal with it. Preventive measures included combating 
mosquitoes, caution about unprotected sex, and avoiding un-
necessary travel. The disease could also be transmitted from 
mother to child and had many side effects on the fetus, includ-
ing microcephaly. Therefore, care of pregnant women was one 
of the main components of the combat against this virus. The 
only factor that hindered the fight against the disease was the 
lack of cooperation from the families involved in  disease. Af-
ter controlling the outbreak, infected cases are still reported 
[11, 12].
Another example of an infectious disease outbreak with some 
similar characteristics to COVID-19 was Ebola epidemic, with 
no certain drug or vaccine at that moment, which was con-
trolled but not eradicated. Ebola was first detected concurrent-
ly in Zaire and Sudan and mounted up to 602 cases and 431 
deaths totally. To prevent further outbreaks, screening for sus-
pected individuals was performed and confirmed cases were 
isolated [13]. In 2014-2016, Ebola re-emerged in West Africa 
with a greater incidence rate. Final operations to control the 
disease included advancement of diagnosis and treatment fa-
cilities, improving society hygiene, isolating patients and trav-
elers and applying strict border surveillance [14]. 
In conclusion, isolation and quarantine are the key tools in 
combating against emerging infectious diseases which their 
specific treatment and vaccine have not been developed yet. 
This strategy seems to be effective in COVID-19 control and 
might lead to eradication. However, there is a probability that 
in some areas the disease may remain endemic for years. An-
other probability is that as the weather warms up, the transmis-
sion rate becomes lower and the infected cases decline. It might 
be helpful but is not enough alone. In addition, in the lack of 
vaccine development, other outbreaks might occur. Reducing 
the transmission rate would buy us time with the development 
of potential vaccines and medications. A global collaboration 
from the scientists to the people and governments is needed 
to decrease the transmission rate and finally overcome the dis-
ease.
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